IL31 and primary cutaneous T-cell non-Hodgkin lymphoma: Concerning the therapeutic implications of IL-31 in CTCL, Cedeno-Laurent et al. [113] showed a decrease in IL-31 expression for PBMCs treated in vitro with vorinostat, a histone-deacetylase inhibitor (HDACi), or with dexamethasone in patients with stage IV CTCL.